DEI Special Edition Spring / Summer 2024
This underrepresentation extends beyond just demographics, encompassing socio - economic factors, geographic locations, and cultural nuances that can influence health outcomes. There are several barriers to increasing diversity in clinical trials, which in- clude: • Historical Exclusion • Mistrust • Inconvenience • Lack of Awareness • Eligibility Criteria and Enrollment Practices • Limited Access to Healthcare
PATH FORWARD: Regulatory authorities, pharmaceutical industry and other research stakeholders rec- ognize the impact of this issue and have started to heighten their emphasis on inclu- sivity in clinical trials. BUT A PLAN IS ONLY GOOD AS ITS ACTIONS: Planning to improve diverse participation in clinical trials is a crucial step, but its effectiveness remains limited until translated into action by multiple research stake- holders with parallel accountability from regulatory bodies. WHY? • Historical Disparities Persist: Despite intentions to address di- versity issues, historical disparities persist. Mere planning does not rectify the deep - rooted challenges related to underrepresen- tation of specific demographic groups in clinical trials. Concrete actions are needed to break this cycle. • Inertia in Research Practices: The inertia in research practices, often shaped by longstanding protocols and methodologies, can hinder the implementation of inclusive strategies. Transforming these practices requires proactive measures, and planning alone may not suffice to overcome established habits.
40
Made with FlippingBook - professional solution for displaying marketing and sales documents online